3//SEC Filing
OrbiMed Capital GP VI LLC 3
Accession 0001209191-20-061722
CIK 0001671858other
Filed
Dec 2, 7:00 PM ET
Accepted
Dec 3, 8:57 PM ET
Size
12.9 KB
Accession
0001209191-20-061722
Insider Transaction Report
Form 3
ORBIMED ADVISORS LLC
Director10% Owner
Holdings
- 269,323(indirect: By OrbiMed Private Investments VI, LP)
Common Stock
- (indirect: By OrbiMed Private Investments VI, LP)
Series A Preferred Stock
→ Common Stock (3,462,737 underlying) - 269,323(indirect: By LLC)
Common Stock
- (indirect: By OrbiMed Private Investments VI, LP)
Series C Preferred Stock
→ Common Stock (1,055,287 underlying) - (indirect: By OrbiMed Private Investments VI, LP)
Series B Preferred Stock
→ Common Stock (2,493,741 underlying)
OrbiMed Capital GP VI LLC
Director10% Owner
Holdings
- 269,323(indirect: By LLC)
Common Stock
- (indirect: By OrbiMed Private Investments VI, LP)
Series C Preferred Stock
→ Common Stock (1,055,287 underlying) - (indirect: By OrbiMed Private Investments VI, LP)
Series B Preferred Stock
→ Common Stock (2,493,741 underlying) - 269,323(indirect: By OrbiMed Private Investments VI, LP)
Common Stock
- (indirect: By OrbiMed Private Investments VI, LP)
Series A Preferred Stock
→ Common Stock (3,462,737 underlying)
Footnotes (4)
- [F1]These securities are held of record by OrbiMed Private Investments VI, LP ("OPI VI"). OrbiMed Capital GP VI LLC ("GP VI") is the general partner to OPI VI and OrbiMed Advisors LLC ("Advisors") is the managing member of GP VI. By virtue of such relationships, GP VI and Advisors may be deemed to have voting and investment power with respect to the shares held by OPI VI. Both GP VI and Advisors may be deemed to directly or indirectly, including by reason of their mutual affiliation, to be beneficial owners of the shares held by OPI VI. Advisors exercise investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the shares of OPI VI.
- [F2]This report on Form 3 is jointly filed by Advisors and GP VI. Each of the Reporting Persons disclaim beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, Peter Thompson, an employee of Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose.
- [F3]These securities are held of record by OPI VI - IP HoldCo LLC ("HoldCo"). OPI VI - IP TopCo LLC ("TopCo") is the sole member of HoldCo. OrbiMed Private Investments VI - IP, LP ("OPI VI IP") is the sole member of TopCo. GP VI is the general partner of OPI VI IP. Advisors is the managing member of GP VI. By virtue of such relationships, Advisors and GP VI may be deemed to have voting and investment power over the securities held by HoldCo and as a result, may be deemed to have beneficial ownership over such securities. Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the shares held by HoldCo.
- [F4]All outstanding shares of Preferred Stock will automatically convert into shares of Common Stock immediately upon the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration at a rate of 1 share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock has no expiration date.
Documents
Issuer
Silverback Therapeutics, Inc.
CIK 0001671858
Entity typeother
IncorporatedDE
Related Parties
1- filerCIK 0001682115
Filing Metadata
- Form type
- 3
- Filed
- Dec 2, 7:00 PM ET
- Accepted
- Dec 3, 8:57 PM ET
- Size
- 12.9 KB